Clinical Trial Detail

NCT ID NCT03077828
Title Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Northwestern University
Indications

Hodgkin's lymphoma

Therapies

Pembrolizumab + Etoposide + Carboplatin + Ifosfamide

Age Groups: adult senior

No variant requirements are available.